Bill Lawrence, PhD is a longevity researcher and biogerontology scientist specializing in Khavinson Peptide Bioregulators, biological aging, and epigenetic regulation. His work focuses on translating decades of Eastern European and Russian research on short regulatory peptides into frameworks accessible to Western clinicians and researchers. Dr. Lawrence is closely associated with the scientific legacy of Vladimir Khavinson, MD, PhD, whose laboratory and clinical studies investigated organ-specific peptide bioregulators that regulate gene expression, tissue repair, and age-related functional decline. Dr. Lawrence’s role has centered on mechanistic interpretation, clinical synthesis, and biomarker-anchored evaluation, particularly using epigenetic aging measures, telomere biology, and systems-level biomarkers. Dr. Lawrence is the administrator of two biological age interventional clinical studies. Khavinson Peptide Bioregulators have demonstrated potential for cellular reprogramming and organ regeneration, with his studies showing telomerase activation equivalent to reducing biological age by 22 years and a projected 56% decrease in all-cause mortality.